公开(公告)号：US20190167770A1

公开(公告)日：2019-06-06

申请号：US16210248

申请日：2018-12-05

申请人： AERase, Inc.

发明人： Scott W. ROWLINSON ,  Anthony G. QUINN

IPC分类号： A61K38/50 ,  A61K9/00 ,  A61K48/00 ,  A61K47/60 ,  A61K45/06 ,  A61P3/00

摘要： A method and composition to treat a subject with arginase 1 (ARG1) deficiency (ARG1-D) and to rapidly reduce the levels of at least one of arginine and/or a guanidino compound in the subject.

公开(公告)号：US20140242060A1

公开(公告)日：2014-08-28

申请号：US14275259

申请日：2014-05-12

申请人： Aerase, Inc.

发明人： George GEORGIOU ,  Everett STONE

IPC分类号： C12N9/78

CPC分类号： A61K38/50 ,  A61K33/24 ,  A61K38/00 ,  A61K47/60 ,  A61K47/64 ,  C12N9/78 ,  C12Y305/03001

摘要： Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.

摘要翻译： 描述了用于治疗癌症的组合物和方法，更优选地描述了在精氨酸琥珀酸合成酶中不表达或以其他方式缺乏的癌症的治疗，其中所述酶在血清中消耗L-精氨酸。 在一个实施方案中，本发明考虑了与天然人精氨酸酶I相比，包含至少一个氨基酸取代和金属辅因子的精氨酸酶蛋白，例如人精氨酸酶I蛋白，所述蛋白质包含增加的催化活性。

公开(公告)号：US20240009284A1

公开(公告)日：2024-01-11

申请号：US18344083

申请日：2023-06-29

申请人： AERase, Inc.

发明人： Scott W. ROWLINSON ,  Anthony G. QUINN ,  Ann LOWE ,  David LOWE

IPC分类号： A61K38/50 ,  A61K9/00 ,  A61K48/00 ,  A61K45/06 ,  A61P3/00 ,  A61K47/60 ,  A61K38/51

CPC分类号： A61K38/50 ,  A61K9/0019 ,  A61K48/005 ,  C12Y305/03001 ,  A61K45/06 ,  A61P3/00 ,  A61K47/60 ,  A61K38/51

摘要： A method and composition to treat a subject with arginase 1 (ARG1) deficiency (ARG1-D) and to rapidly reduce the levels of at least one of arginine and/or a guanidino compound in the subject.

公开(公告)号：US10729752B2

公开(公告)日：2020-08-04

申请号：US15699951

申请日：2017-09-08

申请人： AERASE, INC.

发明人： David Lowe ,  Scott W. Rowlinson ,  Susan Alters ,  Giulia Agnello

IPC分类号： A61K38/50 ,  A61K39/395 ,  C07K16/28 ,  A61P35/00 ,  C07K19/00 ,  C12N9/78 ,  A61K9/00 ,  A61K39/00

摘要： Methods of treating tumors or cancer include administration of an arginine depleting enzyme and an immune-oncology agent.

公开(公告)号：USRE46423E1

公开(公告)日：2017-06-06

申请号：US14711916

申请日：2015-05-14

申请人： AERASE, INC.

发明人： George Georgiou ,  Everett Stone

IPC分类号： A61K38/46 ,  C07H21/04 ,  C12N9/78 ,  C12N9/14 ,  C12N9/96 ,  A61K38/50 ,  A61K47/48 ,  A61K38/00

CPC分类号： A61K38/50 ,  A61K33/24 ,  A61K38/00 ,  A61K47/48215 ,  A61K47/60 ,  C12N9/78 ,  C12Y305/03001

摘要： Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.

公开(公告)号：US10098933B2

公开(公告)日：2018-10-16

申请号：US15270955

申请日：2016-09-20

申请人： AERASE, Inc.

发明人： George Georgiou ,  Everett Stone

IPC分类号： A61K38/46 ,  C12N9/14 ,  C12N9/78 ,  C12N9/96 ,  C07H21/04 ,  A61K38/50 ,  A61K47/48 ,  A61K33/24 ,  A61K38/00

摘要： Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.

公开(公告)号：US20170128553A1

公开(公告)日：2017-05-11

申请号：US15270955

申请日：2016-09-20

申请人： AERASE, Inc.

发明人： George Georgiou ,  Everett Stone

IPC分类号： A61K38/50 ,  A61K33/24

CPC分类号： A61K38/50 ,  A61K33/24 ,  A61K38/00 ,  A61K47/48215 ,  A61K47/60 ,  C12N9/78 ,  C12Y305/03001

摘要： Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, trgininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.

公开(公告)号：US09050340B2

公开(公告)日：2015-06-09

申请号：US13863448

申请日：2013-04-16

申请人： AERASE, INC.

发明人： George Georgiou ,  Everett Stone

IPC分类号： A61K38/46 ,  C12N9/14 ,  C12N9/78 ,  C12N9/96 ,  C07H21/04 ,  A61K38/50 ,  A61K47/48 ,  A61K38/00

CPC分类号： A61K38/50 ,  A61K33/24 ,  A61K38/00 ,  A61K47/48215 ,  A61K47/60 ,  C12N9/78 ,  C12Y305/03001

摘要： Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.

摘要翻译： 描述了用于治疗癌症的组合物和方法，更优选地描述了在精氨酸琥珀酸合成酶中不表达或以其他方式缺乏的癌症的治疗，其中所述酶在血清中消耗L-精氨酸。 在一个实施方案中，本发明考虑了与天然人精氨酸酶I相比，包含至少一个氨基酸取代和金属辅因子的精氨酸酶蛋白，例如人精氨酸酶I蛋白，所述蛋白质包含增加的催化活性。

公开(公告)号：US20240009283A1

公开(公告)日：2024-01-11

申请号：US18160112

申请日：2023-01-26

申请人： Aerase, Inc.

发明人： George Georgiou ,  Everett Stone

IPC分类号： A61K38/50 ,  A61K47/60 ,  C12N9/78 ,  A61K33/24 ,  A61K47/64

CPC分类号： A61K38/50 ,  C12Y305/03001 ,  A61K47/60 ,  C12N9/78 ,  A61K33/24 ,  A61K47/64 ,  A61K38/00

摘要： Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.

公开(公告)号：US11717562B2

公开(公告)日：2023-08-08

申请号：US16210248

申请日：2018-12-05

申请人： AERase, Inc.

发明人： Scott W. Rowlinson ,  Anthony G. Quinn ,  Ann Lowe ,  David Lowe

IPC分类号： A61K38/00 ,  A61K47/00 ,  A61K38/50 ,  A61K9/00 ,  A61K48/00 ,  A61K45/06 ,  A61P3/00 ,  A61K47/60 ,  A61K38/51

CPC分类号： A61K38/50 ,  A61K9/0019 ,  A61K38/51 ,  A61K45/06 ,  A61K47/60 ,  A61K48/005 ,  A61P3/00 ,  C12Y305/03001

摘要： A method and composition to treat a subject with arginase 1 (ARG1) deficiency (ARG1-D) and to rapidly reduce the levels of at least one of arginine and/or a guanidino compound in the subject.